Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394994 | 0.87 | DRD2 (0.46) | DRD2ADRA1AMAPTMAPK1KMT2A | |
| SCHEMBL4811463 | 0.85 | DRD2 (0.47) | DRD2ADRA1AMAPTHTTKMT2A | |
| SCHEMBL5319797 | 0.84 | DRD2 (0.49) | DRD2ADRA1ATP53MAPK1KMT2A | |
| SCHEMBL4615593 | 0.83 | DRD2 (0.66) | DRD2ADRA1A | |
| SCHEMBL4617774 | 0.83 | DRD2 (0.54) | DRD2ADRA1AMAPTHTTTP53 | |
| SCHEMBL4811543 | 0.82 | LMNA (0.46) | DRD2ADRA1AKMT2AKCNH2LMNA | |
| SCHEMBL4616768 | 0.82 | DRD2 (0.50) | DRD2ADRA1AMAPTHTTTP53 | |
| SCHEMBL4617038 | 0.81 | DRD2 (0.51) | DRD2ADRA1AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4616552 | 0.81 | CXCR3 (0.42) | DRD2ADRA1AKMT2AMEN1 | |
| SCHEMBL4617195 | 0.81 | DRD2 (0.49) | DRD2ADRA1AMAPTHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139555-A1 | Arylthiobenzylpiperidine Derivatives | H. LUNDBECK A/S (DK) | 2008-06-12 | — | — | US | disclosed |
| US-7329656-B2 | Arylthiobenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2008-02-12 | — | — | US | disclosed |
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | H. LUNDBECK A/S | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | MCHR1, MTNR1A, MTNR1B | DRD2 156/4885ADRA1A 75/4885MAPT 1997/4885 |
| US-20080139555-A1 | Arylthiobenzylpiperidine Derivatives | MCHR1, MC4R, MCHR2 | DRD2 210/4885ADRA1A 54/4885MAPT 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.